A federal judge handed Otsuka Pharmaceutical Co. Ltd. a victory Monday in its bid to keep a slew of companies, including Teva Pharmaceutical Industries Ltd., Apotex Inc. and Sandoz Inc., from producing generic versions of its blockbuster schizophrenia drug Abilify®. Judge Mary L. Cooper of the U.S. District Court for the District of New Jersey ruled that the patent covering Abilify® is valid and enforceable and enjoined the defendants from marketing their copycat versions of the drug until Otsuka's patent expires April 20, 2015. Abilify® is the sixth-largest-selling pharmaceutical in the U.S., and it had more than $3.3 billion in sales in 2009, according to Otsuka. “This is the outcome we were hoping for, and we're very pleased with the result,” said James Monroe, partner at Finnegan, who represents Otsuka.
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Award/Ranking
The National Law Journal Names Finnegan the Top Intellectual Property Law Department in DC
June 24, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.